FLU-v
Phase 3- Indications
- Influenza
Company intelligence / Profile preview
ConserV Bioscience
London, England, United Kingdomconservbio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 3
01
Overview
The universal influenza vaccine demonstrated protection from disease in a Phase II challenge study. The company’s pipeline includes multiple candidates at various stages of development against high-priority infectious diseases using both pathogen-targeted and vector saliva-targeted strategies.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Synthetic multi-epitope peptidesmRNA vaccinesRecombinant proteinsPeptide-based vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Lawrence Livermore National Laboratory – pan-coronavirus vaccine collaboration using NLP technologyWalter Reed Army Institute of Research – malaria vaccine research collaborationUniversity of Leeds & KU Leuven – Aedes-transmitted disease vaccines project funded by UK Department of Health & Social Care / UK Vaccine NetworkUniversity of Maryland – pan-coronavirus project partner/funder via DHSC/UKVN grant support
Beyond the preview
Go deeper on ConserV Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ConserV Bioscience.